Pharmacokinetics of hypoglycaemic sulfonamides: OZIDIA, a new concept;Pharmacocinetique des sulfamides hypoglycemiants: OZIDIAρ un nouveau concept

Diabetes and Metabolism

Volumn 23, Issue SUPPL. 4, 1997, Pages 39-43

  Selam, J L ^a  

^a HÔTEL DIEU   (France)

Author keywords

Glipizide; Pharmacokinetics; Sulfonylurea

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIPIZIDE; OZIDIA; SULFONAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG ACCUMULATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULINEMIA; LIVER METABOLISM; ORAL DRUG ADMINISTRATION; REVIEW; CIRCADIAN RHYTHM; LIVER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PATHOPHYSIOLOGY; SECRETION;

ADMINISTRATION, ORAL; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; LIVER;

EID: 17144451235     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiadiazol (le VK 57 ou 2254 RP). Montpellier Med, 1942, 21, 441.
2. Loubatieres A. The hypoglycemic sulfonamides : history and development of the problem for 1942 to 1955. Ann NY Acad Sci, 1957, 4-11.
3. Melander A, Bitzen PO, Faber O, Groop L. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs, 1989, 37, 58-72.
4. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clinical Pharmacokinetics, 1987, 12, 379-401.
5. Groop LC. Sulfonylureas in NIDDM. Diabetes Care, 1992, 15, 737-754.
6. Gerich JE. Oral hypoglycemic agents. N Engl J Med., 1989, 321, 1231-1245.
7. Boden G, Chen X, urbain JL. Evidence for a circadian rhythm of insulin sensibility in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes, 1996, 45, 1044-1050.
8. Faber OK, Beck-Nielson, Binder C, Butzer P, Damsgaard EM, Froland F, Hjolland E, Lindskov HO, Melander A, Pedersen O, Petersen P, Schwarts Sorensen N, Wahlin-Boll E. Acute actions of sulfonylurea drugs during long-term treatment of NIDDM. Diabetes Care, 1990, 13, 26-31.
9. Wahlin-Boll E, Groop L, Karhumaa S, Groop PH, Totterman KJ, Melander A. Therapeutic equivalence of once- and thrice-daily Glipizide. Eur. J Clin Pharmacol, 1986, 31, 95-99.
10. Groop L, Groop PH, Stenman S, Saloranta C, Totterman KJ, Fyhrquist F, Melander A.Comparison of pharmacokinetics metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care, 1987, 10,671-78.
11. Draeger E. Clinical profile of glimepiride. Diab Res Clin Pract, 1995, 28 suppl, S139-S146.
12. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety, 1994, 11 (4), 223-241.
13. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care, 1989, 12, 203-208.
14. Girardin E, Vial T, Pham E, Evreux JC. Hypoglycémies induites par les sulfamides hypoglycémiants. Ann. Med. Interne, 1992, 143, 11-17.
15. Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. Brit Med J, 1988, 296, 949-950.
16. Campbell IW. Hypoglycaemia and type 2 diabetes : sulphonylureas. In Frier B.N., Fischer B.N., Editors, Hypoglycaemia and diabetes, London, Edward Arnold, 1993, 387-39.
17. Hazard J. Accidents hypoglycémiques provoqués par les sulfamides hypoglycémiants. Nouv. Presse Méd, 1976, 5, 903-905.
18. UK Prospective Diabetes Study Group : Overview of 6 years' therapy of type Ii diabetes : a progressive disease. Diabetes, 1995,44, 1249-1258.
19. Balant L, Zahnd G, Gorgin A, Schwarz R, Fabre J. Pharmacokinectics of glipizide in man : influence of renal insufficiency. Diabetologia, 1973, 9, 331-338.
20. Selam JL, Medlej R, M'bemba J, Chevalier A, Guyon F, Ashworth L, Slama G. Symptoms, hormones, and glucose fluxes during a gradual hypoglycaemia induced by intraperitoneal vs venous insulin infusion in type I diabetes. Diabetic Medicine, 1995, 12, 1102-1109.
21. Swanson DR, Barckay BL, Wong PSL, Theeuwes F. Nifedipine gastrointestinal therapeutic system. Am J Med, 1987, 83 (suppl. 68), 3-9.
22. Dossier d'AMM. Pfizer
23. Wahlin-Boll E, Melander A, Sartor G, Schersten B. Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects. Eur. J. Clin. Pharmacol, 1980, 18, 279-283.
24. Berelowitz M, Go E, Brook S. Contrasting influences of glipizide GITS and glyburide on fasting and post sustacal glycemia, glucose production, and 24 h glucose/insulin profiles in NIDDM. ADA, 1996, 285A.
25. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Efficacité comparative d'une formulation monoprise de glipizide à libération contrôlée et du glipizide standard chez des patients atteints de DNID. Diabetes Care, 1994, 12, 1460-1464.